A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta

Area of Science:

• Pediatric Endocrinology
• Orthopedics
• Pharmacology

Background:

• Intravenous bisphosphonates are established treatments for osteogenesis imperfecta, improving bone mineral density and fracture rates in children.
• The efficacy of oral bisphosphonates for treating osteogenesis imperfecta in pediatric populations remains largely unestablished.
• Osteogenesis imperfecta is a genetic disorder characterized by fragile bones, leading to frequent fractures and impaired growth.

Purpose of the Study:

• To compare the efficacy of oral alendronate versus intravenous pamidronate in children diagnosed with osteogenesis imperfecta.
• To evaluate the impact of both bisphosphonate formulations on bone mineral density, bone turnover markers, fracture incidence, and linear growth.

Main Methods:

• An open-label, prospective, randomized clinical trial was conducted.
• Pediatric patients were stratified by bone age, pubertal stage, and osteogenesis imperfecta type.
• Participants received either intravenous pamidronate (3 mg/kg every 4 months) or oral alendronate (10-20 mg daily).

Main Results:

• Both oral and intravenous bisphosphonate groups demonstrated comparable increases in bone mineral density, exceeding normal growth expectations.
• A significant decrease in biochemical markers of bone turnover was observed in all treated children.
• Moderate increases in linear growth and a non-significant reduction in fracture incidence were noted in both treatment arms.

Conclusions:

• Oral alendronate appears to be an effective alternative to intravenous pamidronate for managing osteogenesis imperfecta in children.
• Both treatment regimens positively impact bone metabolism and density, offering potential benefits for growth and fracture prevention.
• Further research with larger cohorts is warranted to confirm long-term efficacy and safety profiles.